Rick DeLuca is executive vice president and president, Animal Health for Merck. Rick has worldwide responsibility for the Animal Health business, a position he has held since 2011. Under Rick’s leadership, Merck’s Animal Health business has become an industry leader that offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products.
Prior to joining Merck, Rick spent more than two decades in positions of increasing scope and responsibility at Wyeth, including president of Animal Health, chief operating officer and chief financial officer of Animal Health, vice president of finance global pharmaceuticals and director audit. He was also a member of Wyeth’s executive, operations, law and regulatory and human resources and benefits committees.
Rick was board chairman of Health for Animals, the global animal health industry association, from 2017 to 2020. He is also board chairman of Animal Health Institute, the U.S. animal medicines industry association, a position he has held since 2016. Rick received his B.A. in business administration from Widener University. He is a certified public accountant and certified management accountant.
What is Richard R. Deluca's net worth?
The estimated net worth of Richard R. Deluca is at least $11.27 million as of November 8th, 2023. Mr. Deluca owns 111,764 shares of Merck & Co., Inc. stock worth more than $11,271,399 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Deluca may own. Learn More about Richard R. Deluca's net worth.
How do I contact Richard R. Deluca?
Has Richard R. Deluca been buying or selling shares of Merck & Co., Inc.?
Richard R. Deluca has not been actively trading shares of Merck & Co., Inc. during the last ninety days. Most recently, Richard R. Deluca sold 43,823 shares of the business's stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $105.03, for a transaction totalling $4,602,729.69. Following the completion of the sale, the executive vice president now directly owns 111,764 shares of the company's stock, valued at $11,738,572.92. Learn More on Richard R. Deluca's trading history.
Who are Merck & Co., Inc.'s active insiders?
Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Cristal Downing (Insider), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Inge Thulin (Director), Ashley Watson (SVP), Wendell Weeks (Director), and David Williams (Executive vice president, chief information & digital officer). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?
During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 2,833 shares worth more than $250,012.25. During the last year, insiders at the sold shares 3 times. They sold a total of 15,237 shares worth more than $1,282,329.74. The most recent insider tranaction occured on November, 3rd when EVP David Michael Williams sold 8,614 shares worth more than $720,044.26. Insiders at Merck & Co., Inc. own 0.1% of the company.
Learn More about insider trades at Merck & Co., Inc.. Information on this page was last updated on 11/3/2025.
